numbers raised at UBS. Shares of CVS now seen reaching $48, according to UBS. Estimates also increased on deeper drive on generic pipeline. Buy rating.
target raised at Oppenheimer to $130. Higher than expected crude oil prices. Outperform rating.
estimates, target raised at UBS. Shares of ESRX now seen reaching $66, according to UBS. Estimates also increased on Medco merger. Buy rating.
numbers lowered at BMO Capital Markets. Shares of INFY now seen reaching $46. Estimates also lowered on disappointing guidance. Perform rating.
numbers cut at Benchmark. Shares of JDAS now seen reaching $38, according to Benchmark. Estimates also reduced, to match the company's new guidance. Overweight rating.
estimates, target reduced at Guggenheim. NE estimates were cut through 2013, Guggenheim said. New fleet status report shows increased downtime. Buy rating and new $41 price target.
numbers raised at Goldman. Shares of PAG now seen reaching $23, according to Goldman Sachs. Estimates also increased, as the recent UK acquisition should add to earnings. Neutral rating.
numbers increased at Goldman. TSCO estimates were raised through 2013, Goldman Sachs said. Management boosted guidance. Neutral rating and new $82 price target.
numbers lowered at Goldman. Shares of WPI now seen reaching $78, according to Goldman Sachs. Company is facing increased competition. Buy rating and new $78 price target.
Wolverine World Wide
numbers cut at Credit Suisse. WWW estimates were lowered through 2013, Credit Suisse said. as sales could be hurt by unseasonably warm weather this winter. Outperform rating.
target lowered at Citigroup to $118, according to Citigroup. Company has still not received formal approval for land in Cotai. Neutral rating.
>To submit a news tip, email:
and become a fan on